Bristol-Myers Squibb Co and Eisai Co to jointly develop, market experimental cancer drug

In a statement, Bristol-Myers Squibb Co and Eisai Co said, they had entered into an agreement to jointly develop and market an experimental cancer drug worth up to $3.10 billion.

Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, said the companies.

Both companies will jointly develop and market the drug, MORAb-202, in the United States, Canada, Europe, and Asia.

Earlier this year in May, Bristol-Myers entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell lung cancer.

Eisai’s drug, MORAb-202, is being developed for the treatment of solid tumors, including ovarian, lung and breast cancers and is in the early stage of development.

Bristol-Myers will pay Eisai a royalty on sales outside of the collaboration territories, said both companies.

Categories: Creativity, Entrepreneurship, HR & Organization, Strategy

Tags: , , , , , , , , , , , , , , , , , , , , , , , , ,

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: